Text Size
25 studies found for:    Open Studies | "Measles"

Modify this search | How to Use Search Results

Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Measles"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Unknown † Measles Vaccine in Patients With Measles Virus-Positive, Advanced Non-Small Cell Lung Cancer
Conditions: Non-Small Cell Lung Cancer;   Measles
Intervention: Biological: attenuated measles vaccine
2 Recruiting Additional Measles Vaccine at 4 Months of Age
Condition: Measles Infection
Intervention: Biological: Measles vaccine
3 Not yet recruiting Immunity to Measles Virus in the Thai Population Age 18-30 Years and Predictive Factors
Condition: Measles
Intervention:
4 Not yet recruiting Induction of Immunity Against Measles in Pediatric Liver Transplant Recipients
Condition: Measles
Intervention: Biological: MMR vaccination
5 Recruiting Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations
Conditions: Measles;   Mumps;   Rubella
Intervention: Biological: MMR Vaccine
6 Not yet recruiting Safety Study of Measles-Mumps-Rubella-Varicella (MMRV) Vaccine, Priorix-Tetra™ in Children Living in the Philippines
Conditions: Mumps;   Rubella;   Measles;   Varicella
Interventions: Biological: Priorix-Tetra™;   Other: Safety data collection
7 Recruiting Trial of Additional Measles Vaccine to Reduce Child Mortality
Condition: Measles Vaccine
Intervention: Biological: Early measles vaccine
8 Not yet recruiting Trial of Additional Measles Vaccine to Reduce Child Mortality. Burkina Faso.
Condition: Measles Vaccine
Intervention: Biological: Early measles vaccine
9 Recruiting Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age
Condition: Measles, Mumps and Rubella Diseases
Interventions: Biological: Priorix®;   Biological: Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine (also known as M-M-R Vax Pro™);   Biological: Kinrix®;   Biological: Varivax®
10 Unknown † Ontogeny of Measles Immunity in Infants
Condition: Measles
Interventions: Biological: Attenuvax (Measles Virus Live Vaccine, 0.5ml subcutaneous);   Biological: MMR-II (Measles-Mumps-Rubella Virus Live Vaccine, 0.5ml subcutaneous)
11 Recruiting Coadministration of Measles-rubella and Rotavirus Vaccines
Conditions: Measles Antibody Seroconversion;   Rubella Antibody Seroconversion;   Rotavirus GMT;   Rotavirus IgA Seropositivity
Interventions: Biological: Rotarix vaccine;   Biological: measles-rubella vaccine
12 Recruiting A Clinical Trial to Assess the Safety of a Measles Vaccine (Dry Powder) Administered by Two Different Devices
Condition: Prophylaxis for the Measles Infection
Interventions: Biological: Dry Powdered Measles Vaccine;   Biological: Licensed Subcutaneous Measles Vaccine
13 Recruiting Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life
Condition: Measles, Mumps and Rubella Diseases
Interventions: Biological: GSK Bilogicals measles, mumps and rubella vaccine live (GSK 209762).;   Biological: Merck & Co., Inc.'s M-M-R®II, combined measles-mumps-rubella virus vaccine live.;   Biological: Varivax® (Merck & Co., Inc.);   Biological: Havrix®;   Biological: Prevnar 13® (Pfizer Inc.)
14 Recruiting Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children
Conditions: Varicella;   Rubella;   Measles;   Mumps
Interventions: Biological: Priorix Tetra;   Biological: Meningitec
15 Unknown † The Influence of Probiotics on the Immunologic Response to Vaccinations in Infants
Conditions: Immunity;   Measles;   Mumps;   Rubella
Interventions: Dietary Supplement: Probiotics (L.acidophilus and B.lactis);   Dietary Supplement: Cornflor
16 Recruiting Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix®) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M M R®II), in Children 12 to 15 Months of Age
Condition: Measles, Mumps and Rubella Diseases
Interventions: Biological: GSK Biologicals measles, mumps and rubella vaccine live (GSK 209762).;   Biological: Merck & Co., Inc.'s M-M-R®II (also called M-M-R Vax Pro®), combined measles-mumps-rubella virus vaccine.;   Biological: Varivax® (Merck & Co., Inc.);   Biological: Havrix®;   Biological: Prevnar 13® (Pfizer Inc.)
17 Recruiting Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma
Conditions: Recurrent Malignant Mesothelioma;   Stage IA Malignant Mesothelioma;   Stage IB Malignant Mesothelioma;   Stage II Malignant Mesothelioma;   Stage III Malignant Mesothelioma;   Stage IV Malignant Mesothelioma
Interventions: Biological: oncolytic measles virus encoding thyroidal sodium iodide symporter;   Other: laboratory biomarker analysis;   Procedure: single photon emission computed tomography;   Procedure: computed tomography
18 Recruiting The Effect on Overall Mortality of a National Policy of Limiting Measles Vaccination to Children Below 12 Months of Age
Conditions: Mortality;   Vaccines
Intervention: Biological: Providing measles vaccine for all children 9-35 months who have not yet received a routine measles vaccine
19 Recruiting Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Conditions: Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions: Biological: carcinoembryonic antigen-expressing measles virus;   Biological: oncolytic measles virus encoding thyroidal sodium iodide symporter;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: laboratory biomarker analysis
20 Recruiting Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: carcinoembryonic antigen-expressing measles virus;   Genetic: fluorescence in situ hybridization;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: immunohistochemistry staining method;   Other: immunologic technique;   Other: laboratory biomarker analysis;   Procedure: adjuvant therapy;   Procedure: conventional surgery;   Procedure: needle biopsy;   Procedure: neoadjuvant therapy
To Top

Previous Page Studies Shown (1-20) Next Page (21-25) Show next page of results
† Indicates status has not been verified in more than two years